Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 2648

1.

[Immediate results of combined therapy for local recurrences of rectal cancer].

Korytova LI, Sandalevskaya AG, Krasnikoval VG, Korytov OV, Meshechkin AV.

Vopr Onkol. 2015;61(1):52-6. Russian.

PMID:
26016146
2.

Quality of life in colorectal cancer patients during chemotherapy in the era of monoclonal antibody therapies.

Teker F, Demirag G, Erdem D, Kemal Y, Yucel I.

J BUON. 2015 Mar-Apr;20(2):443-51.

PMID:
26011334
3.

[A questionnaire survey on QOL and toxicity in colorectal cancer survivors who received adjuvant chemotherapy].

Taniguchi H, Narita Y, Komori K, Kimura K, Kinoshita T, Komori A, Uegaki S, Nomura M, Nitta S, Yamaguchi K, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K.

Gan To Kagaku Ryoho. 2015 Apr;42(4):457-61. Japanese.

PMID:
25963692
4.

The D prefix: toward a reproducible validated alternative end point in rectal cancer.

Glynne-Jones R, West NP, Quirke P.

Dis Colon Rectum. 2015 Jun;58(6):613-6. doi: 10.1097/DCR.0000000000000356. No abstract available.

PMID:
25944434
5.

Impact of adjuvant chemotherapy in patients with curatively resected stage IV colorectal cancer.

Kobayashi H, Kotake K, Sugihara K; Study Group for Peritoneal Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum.

Medicine (Baltimore). 2015 May;94(17):e696. doi: 10.1097/MD.0000000000000696.

PMID:
25929899
6.

Feasibility Assessment of Modified FOLFOX-6 as adjuvant treatment after resection of liver metastases from colorectal cancer: analyses of a multicenter phase II clinical trial (Miyagi-HBPCOG Trial-001).

Katayose Y, Yamamoto K, Nakagawal K, Takemura S, Takahashi M, Nakamura R, Shimamura H, Rikiyama T, Egawa S, Yoshda H, Motoi F, Naitoh T, Unno M.

Hepatogastroenterology. 2015 Mar-Apr;62(138):303-8.

PMID:
25916054
7.

Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin.

Bujko K, Glimelius B, Valentini V, Michalski W, Spalek M.

Eur J Surg Oncol. 2015 Jun;41(6):713-23. doi: 10.1016/j.ejso.2015.03.233. Epub 2015 Apr 13. Review.

PMID:
25911110
8.

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M.

Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7.

PMID:
25862517
9.

Inherited variability in a master regulator polymorphism (rs4846126) associates with survival in 5-FU treated colorectal cancer patients.

Pardini B, Bermejo JL, Naccarati A, Di Gaetano C, Rosa F, Legrand C, Novotny J, Vodicka P, Kumar R.

Mutat Res. 2014 Aug-Sep;766-767:7-13. doi: 10.1016/j.mrfmmm.2014.05.007. Epub 2014 Jun 7.

PMID:
25847265
10.

Distinctive oncological features of stage IIIA colorectal cancer: Analysis of prognostic factors for selective adjuvant chemotherapy.

Park SY, Choi GS, Park JS, Kim HJ, Sakai Y, Hasegawa S, Watanabe T, Kim SH.

J Surg Oncol. 2015 Jun;111(7):882-90. doi: 10.1002/jso.23892. Epub 2015 Apr 6.

PMID:
25847023
11.

Adjuvant chemotherapy for rectal cancer - authors' reply.

Breugom AJ, Swets M, van de Velde CJ.

Lancet Oncol. 2015 Apr;16(4):e155. doi: 10.1016/S1470-2045(15)70110-5. No abstract available.

PMID:
25846091
12.

Adjuvant chemotherapy for rectal cancer.

Hofheinz RD, Rödel C, Burkholder I, Kienle P.

Lancet Oncol. 2015 Apr;16(4):e154-5. doi: 10.1016/S1470-2045(15)70112-9. No abstract available.

PMID:
25846090
13.

Adjuvant chemotherapy for rectal cancer.

Bujko K.

Lancet Oncol. 2015 Apr;16(4):e153. doi: 10.1016/S1470-2045(15)70053-7. No abstract available.

PMID:
25846089
14.

Adjuvant chemotherapy for rectal cancer.

You KY, Bi ZF, Liu YM, Qiu XS.

Lancet Oncol. 2015 Apr;16(4):e152. doi: 10.1016/S1470-2045(15)70048-3. No abstract available.

PMID:
25846088
15.

Adjuvant chemotherapy for rectal cancer.

Petrelli F, Coinu A, Barni S.

Lancet Oncol. 2015 Apr;16(4):e152-3. doi: 10.1016/S1470-2045(15)70050-1. No abstract available.

PMID:
25846087
16.

Leukocyte mitochondrial DNA content: a novel biomarker associated with prognosis and therapeutic outcome in colorectal cancer.

Qu F, Chen Y, Wang X, He X, Ren T, Huang Q, Zhang J, Liu X, Guo X, Gu J, Xing J.

Carcinogenesis. 2015 May;36(5):543-52. doi: 10.1093/carcin/bgv042. Epub 2015 Mar 30.

PMID:
25823896
17.

[The present status of CapeOX as adjuvant chemotherapy for colorectal cancer].

Ishii K, Kanamoto A, Miyanaga S, Noto M, Takeda T, Tani T, Yagi M.

Gan To Kagaku Ryoho. 2015 Mar;42(3):319-22. Japanese.

PMID:
25812500
18.

[Use of herbal medicine for cancer treatment-related toxicities].

Samuels N, Morag O, Maimon Y.

Harefuah. 2015 Jan;154(1):43-6, 67. Hebrew.

PMID:
25796675
19.

[Preoperative chemoradiotherapy for rectal cancer: experience from one centre].

Lescut N, Lepinoy A, Schipman B, Cerda T, Guimas V, Bednarek C, Bosset JF.

Cancer Radiother. 2015 Apr;19(2):98-105. doi: 10.1016/j.canrad.2014.11.011. Epub 2015 Mar 10. French.

PMID:
25769650
20.

Safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin and 5-fluorouracil after mesorectal excision with lateral pelvic lymph node dissection for stage iii lower rectal cancer.

Iwasa S, Souda H, Yamazaki K, Takahari D, Miyamoto Y, Takii Y, Ikeda S, Hamaguchi T, Kanemitsu Y, Shimada Y.

Anticancer Res. 2015 Mar;35(3):1815-9.

PMID:
25750348
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk